This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kyowa Hakko Kirin Co., Ltd.
Drug Names(s): KW-2401, 7-hydroxystaurosporine
Description: UCN-01 is a small molecule cyclin-dependent kinase (CDK) modulator that belongs to the family of drugs called staurosporine analogs which have demonstrated an ability to inhibit multiple kinases involved in cell-cycle progression and apoptosis, including Chk-1 and PDK1.
Deal Structure: In October 2006, Keryx entered into an exclusivelicense agreement with Kyowa Hakko Kogyo for the worldwide development and commercialization rights, excluding Japan, to UCN-01. In accordance with the terms of the agreement, Keryx will make up-front and milestone payments as well as pay royalties on product sales.
In April 2008, Keryx announced that the company will be terminating the license agreement for KRX-0601 (UCN-01) as part of a strategic restructuring.
Additional information available to subscribers only: